
Keywords: سال زندگی سالم تنظیم شده با کیفیت; Multiple sclerosis; Pharmaceutical reimbursement, Decision-making; CHMP; committee for medicinal for human use; ICER; incremental cost-effectiveness ratio; MCID; minimal clinically important difference; MS; multiple sclerosis; PBAC; pharmaceutical benefit